Comparison of high initial and fixed-dose regimens of interferon-α2a in chronic hepatitis C: A randomized controlled trial

Journal of Viral Hepatitis

Volumn 5, Issue 1, 1998, Pages 53-59

  Ouzan, D ^a   Babany, G ^b   Valla, D ^c   Opolon, P ^c  

^a INSTITUT ARNAULT TZANCK   (France)

^b Produits Roche   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Hepatitis C; Interferon; Predictive factors

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; FEMALE; HEADACHE; HEPATITIS; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS HEPATITIS; VIRUS INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; FEMALE; FERRITINS; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 0031874436     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00080.x     Document Type: Article

References (21)

1. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-1462.
2. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 15014.
3. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double blind, placebo-controlled trial. N Engl J Med 1989; 32: 1506-1510.
4. Marcellin P, Boyer N, Giostra E et al. Recombinant human a-interferon in patients with chronic non-A, non-B hepatitis. A multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-397.
5. Causse X, Godinot H, Chevallier M et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 1991; 101: 497-502.
6. Tinè F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol 1991; 13: 192-199.
7. Giostra E, Degott C, Chevallier M et al. Histological study of the effect of interferon alpha therapy for chronic hepatitis. Predictive histological markers for a response. Gastroenterology 1992; 102: A813.
8. Valla D, Babany G, Ouzan D et al. Prevention of relapse in patients with chronic non-A non-B/C hepatitis who respond to alpha interferon. A controlled multicenter trial of low-dose maintenance therapy. J Hepatol 1994; 21: 774-778.
9. International Group. Acute and chronic hepatitis revisited. Lancet 1977; 2: 914-919.
10. Knodell RG, Ishak KG. Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
11. Marcellin P, Pouteau M, Degos F et al. Lack of benefit of escalating dosage of interferon in chronic C hepatitis. Gastroenterology 1995; 109: 156-165.
12. Lino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993; 38: 612-618.
13. Chemello L, Bonetti P, Cavelletto L et al. Randomized trial comparing three different regimes of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.
14. Brouwer JT, Nevens F, Kleter GEM et al. Treatment of chronic hepatitis C: efficacy of interferon dose and analysis of factors predictive of response. Interim report of 350 patients treatment in a Benelux multicenter study. Hepatology 1993; 18: 110A.
15. Serfaty L, Loria A, Giral P, Andréani T, Podevin P, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-17.
16. Pagliaro L, Craxi A, Cammaa C et al. Interferon alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-828.
17. Ouzan D, Renée JJ, Balarac N, Masseyef MF. Ferritin levels influence the response of interferon-alpha in chronic C hepatitis. Hepatology 1992; 16: 216A.
18. Piperno A, D'Alba R, Roffi L, Fargion S, Mancia G, Fiorelli G. Relation between a-interferon response and liver iron stores in chronic hepatitis C. Hepatology 1993; 18: 250A.
19. Martinot-Peignoux M, Marcellin P, Pouteau P et al. Pretreatment serum HCV-RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha-interferon therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
20. Camps J, Garcia-Garnero M, Riezu-Boj I et al. Prediction of sustained remission of chronic hepatitis C after a twelve-month course of alpha-interferon. J Hepatol 1994; 21: 4411.
21. Puig PL, Dussaix E, Altman C et al. Host and viral characteristics affecting the response to Interferon therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1995; 7: 335-340.